EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dose-Dependent Genome-Wide DNA Methylation Remodeling by Metformin Modulates Doxorubicin Sensitivity in Cardiac Cells

Mahmoud Abu Shayeb, Nagham N Hendi, Georges Nemer iD, Hana Hammad, Malek Zihlif, Heba Saadeh, Heba Mansour

Epigenomes · 03.07.2026 · 10 (3) · 44

DOI: 10.3390/epigenomes10030044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epigenomes, online erschienen am 03.07.2026. Verfasst von Mahmoud Abu Shayeb und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Microbiology and Forensic Medicine, Faculty of Medicine, The University of Jordan, Amman 11942, Jordan. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qatar National Library.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Doxorubicin (DOX) is an effective chemotherapeutic agent, but its clinical use is limited by dose-dependent cardiotoxicity. Emerging evidence suggests that epigenetic dysregulation, particularly altered DNA methylation, contributes to DOX-induced cardiac injury. Metformin has been reported to exert cardiometabolic and epigenetic regulatory effects. This study investigated genome-wide DNA methylation changes induced by chronic metformin exposure and their effects on doxorubicin sensitivity in H9c2 cardiomyoblast cells.

Methods

Genome-wide DNA methylation changes induced by chronic metformin exposure were investigated in H9c2 cardiomyoblast cells using whole-genome bisulfite sequencing (WGBS). Cells were treated with metformin (0.7–2.8 mM) for four months prior to DOX exposure. Cellular sensitivity to DOX was evaluated using MTT-based dose–response analysis and IC50 estimation.

Results

DOX reduced cell viability (IC50 = 0.164 µM). Chronic metformin pre-treatment produced a dose-dependent rightward shift in DOX dose–response curves, increasing IC50 values to 0.21, 0.289, and 0.51 µM at 0.7, 1.4, and 2.8 mM metformin, respectively. WGBS revealed distinct separation between treatment groups in principal component analysis. Significant methylation changes (adjusted p-value < 0.05) were identified in genes related to oxidative stress, mitochondrial function, apoptosis, and chromatin regulation.

Conclusions

Chronic metformin exposure induces dose-dependent genome-wide DNA methylation remodeling in cardiac cells and is associated with altered cellular sensitivity to doxorubicin. These findings suggest that metabolic modulation by metformin may influence epigenetic regulation and cellular stress responses relevant to chemotherapy-induced cardiotoxicity.

Schlagwörter

Stichwörter der Autor:innen

DNA methylationbisulfite sequencingcardiotoxicitydoxorubicinepigeneticsmetformin

Autor:innen und Institutionen

  • Department of Pathology, Microbiology and Forensic Medicine, Faculty of Medicine, The University of Jordan, Amman 11942, Jordan.
  • Department of Clinical Pharmacy & Therapeutics, Faculty of Pharmacy, Applied Science Private University (ASU), Amman 11937, Jordan.
  • College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation, Doha P.O. Box 34110, Qatar.
  • Department of Biological Sciences, Faculty of Science, The University of Jordan, Amman 11942, Jordan.
  • Department of Pharmacology, Faculty of Medicine, The University of Jordan, Amman 11942, Jordan.
  • Department of Computer Science, King Abdullah II School of Information Technology, The University of Jordan, Amman 11942, Jordan.

ORCID-Profile: Georges Nemer

Förderung

  • Qatar National Library

Zitieren

APA

Abu Shayeb, M., Hendi, N. N., Nemer, G., Hammad, H., Zihlif, M., Saadeh, H., & Mansour, H. (2026). Dose-Dependent Genome-Wide DNA Methylation Remodeling by Metformin Modulates Doxorubicin Sensitivity in Cardiac Cells. Epigenomes, 10(3), 44. https://doi.org/10.3390/epigenomes10030044

Vancouver

Abu Shayeb M, Hendi NN, Nemer G, Hammad H, Zihlif M, Saadeh H, et al. Dose-Dependent Genome-Wide DNA Methylation Remodeling by Metformin Modulates Doxorubicin Sensitivity in Cardiac Cells. Epigenomes. 2026;10(3):44. doi:10.3390/epigenomes10030044

BibTeX
@article{AbuShayeb2026,
  author = {Abu Shayeb, Mahmoud and Hendi, Nagham N and Nemer, Georges and Hammad, Hana and Zihlif, Malek and Saadeh, Heba and Mansour, Heba},
  title = {Dose-Dependent Genome-Wide DNA Methylation Remodeling by Metformin Modulates Doxorubicin Sensitivity in Cardiac Cells},
  journal = {Epigenomes},
  year = {2026},
  volume = {10},
  number = {3},
  pages = {44},
  doi = {10.3390/epigenomes10030044}
}
Kostenlos starten →